scholarly journals Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients

2011 ◽  
pp. 151 ◽  
Author(s):  
Winnie Yeo ◽  
Chan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nausea And Vomiting ◽  
Antiemetic Therapy ◽  
Breast Cancer Patients ◽  
Therapy Options

Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors

2015 ◽  
Vol 24 (4) ◽  
pp. 1563-1569 ◽  
Author(s):  
George Dranitsaris ◽  
Sasha Mazzarello ◽  
Stephanie Smith ◽  
Lisa Vandermeer ◽  
Nathaniel Bouganim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Cancer Patients ◽  
Nausea And Vomiting ◽  
Antiemetic Therapy ◽  
Breast Cancer Patients ◽  
Multiple Risk Factors ◽  
Multiple Risk ◽  
The Impact

scholarly journals The Efficacy of Olanzapine-Contained Antiemetic Therapy for Breast Cancer Patients: A Systematic Review and Pooled Analysis

2021 ◽  
Author(s):  
Bo-Ya Xiao ◽  
Guo-He Lin ◽  
Zhao-Bo Liu ◽  
Yun-Xiang Tang ◽  
Bi-Cheng Wang
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Placebo Group ◽  
Cancer Patients ◽  
Antipsychotic Agent ◽  
Complete Response ◽  
Pooled Analysis ◽  
Nausea And Vomiting ◽  
Antiemetic Therapy ◽  
Breast Cancer Patients

Abstract Purpose: As an antipsychotic agent that targets multiple neurotransmitter receptors, olanzapine has been added to antiemetic therapies. However, olanzapine is rarely used in the real-world antiemetic strategies for breast cancer patients who suffered chemotherapy-induced nausea and vomiting. Therefore, in this study, we comprehensively reviewed the antiemetic researches related to olanzapine and pooled analyzed the results from clinical studies to confirm the efficacy of olanzapine in preventing nausea and vomiting in breast cancer.Methods: PubMed, Web of Science, EMBASE, and Cochrane Central databases were searched from inception through April 19, 2021. Both prospective and retrospective studies were eligible. The primary outcomes were complete response (defined as no vomiting and no use of rescue medications) and no nausea rate.Results: Five studies were identified in the systematic review, four of which with 466 breast cancer patients were included in the pooled analysis. In the acute period (0-24 hours), the olanzapine group had significantly higher rates of complete response (71.3% vs 48.1%, odds ratio [OR]: 2.66, 95% confidence interval [CI] 1.39-5.11, p = 0.003) and no nausea (70.0% vs 43.0%, OR: 3.55, 95% CI 1.76-7.18, p = 0.04) than the placebo group. While in the delayed period, the olanzapine group was also superior to the placebo group in terms of the complete response (82.5% vs 63.3%, OR: 3.81, 95% CI 1.58-9.15, p = 0.003) and no nausea (66.3% vs 51.9%, OR: 2.08, 95% CI 1.03-4.21, p = 0.04) rates. During the overall period in prospective studies, the proportions of complete response (50.0% vs 34.2%, OR: 1.93, p = 0.04) and no nausea (51.3% vs 25.3%, OR: 3.40, p = 0.0006) in the olanzapine group were higher than those in the placebo group. Conclusion: Highly emetogenic chemotherapy breast patients could benefit from olanzapine-contained antiemetic therapy. Furthermore, since the cost is low, olanzapine is worth further clinical application and promotion.

scholarly journals LEMON AROMATHERAPY AS AN ALTERNATIVE TO REDUCE THE INTENSITY OF CHEMOTHERAPY-RELATED NAUSEA AND VOMITING EXPERIENCED BY THE BREAST CANCER PATIENTS

2021 ◽  
Vol 5 (2) ◽  
pp. 125-130
Author(s):  
Puji Hastuti ◽  
Yuli Nurhayati ◽  
Dwi Ernawati ◽  
Christina Yuliastuti ◽  
Merina Widyastuti
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Sampling Technique ◽  
Complementary Therapy ◽  
Nausea And Vomiting ◽  
Wilcoxon Test ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Post Test ◽  
Abnormal Tissue

ABSTRACT Introduction : The mechanism of breast cancer is the cells growing and breeding become appear abnormal tissue of breast. One of the common treatments for it is chemotherapy using cytotoxic drugs. However, chemotherapy may cause nausea and vomiting as its side effects. Lemon aromatherapy is a complementary therapy in patients with breast cancer who experience nausea or vomiting. The study’s purpose was to know the effect of lemon aromatherapy on the intensity of nausea and vomiting experienced by the breast cancer patients as an effect of chemoterapy in the Chemo Center Room of RSAL Dr. Ramelan Surabaya. Material and Methods : The study was the pre-experimental design with pre-post test without control group. There are two variables, lemon aromatherapy is independent, and the intensity of nausea and vomiting is dependent. The sampling technique was nonprobability purposive sampling, with 34 breast cancer patients taken as the sample. A questionnaire was the instrument for collecting the data. The Data collected were analyzed using the Wilcoxon Test (α = 0,05). Results : The study’s result indicated that the lemon aromatherapy was effectively to decrease of the intensity of nausea and vomiting exeperienced by the respondents, with the value of Wilcoxon test p < 0.001. Conclusion : Lemon aromatherapy stimulates the raphe nucleus to produce serotonin. Which function to generate a sense of comfort and calm. For that reason, it can be used as an alternative for taking care of nausea and vomiting experienced by patients with breast cancer as the side effect of chemotherapy. Keywords:  Lemon Aromatherapy, Nausea, Vomiting, Chemotherapy  

Anticipatory Nausea and Vomiting Among Ovarian, Lymphoma, and Breast Cancer Patients Receiving Chemotherapy: Implications for Behavioural Treatment

1992 ◽  
Vol 9 (1) ◽  
pp. 25-31
Author(s):  
Peter W. Dunne ◽  
Matthew R. Sanders ◽  
John H. Kearsley
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Nausea And Vomiting ◽  
Future Research ◽  
Breast Cancer Patients ◽  
Anticipatory Nausea ◽  
Anticipatory Anxiety ◽  
Behavioural Treatment ◽  
Anticipatory Nausea And Vomiting

Cancer patients undergoing chemotherapy frequently experience anticipatory distress before treatment sessions. Eighty-six cancer patients (ovarian, lymphoma and breast) were assessed to determine the prevalence of anticipatory nausea and vomiting (ANV). Approximately one patient in three reported anticipatory nausea (AN), and of these 6 also experienced anticipatory vomiting (AV). Several patients reported anticipatory anxiety without any sensation of nausea. Clinically the notion of anticipatory distress may be more fruitful so that the problem of pretreatment anxiety is also addressed. Generally, AN was rated as moderate or worse in severity, occurred fairly consistently, and often began well before arrival at hospital on treatment day. It is suggested that future research should endeavour to link more closely the topography of the problem and the intervention techniques employed, as well as evaluating a broader range of possible interventions.

Analysis of pretreatment nonpharmacologic, pharmacologic factors, and yoga intervention on CINV outcomes in breast cancer patients undergoing adjuvant chemotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1093-1093
Author(s):  
Malur R. Usharani ◽  
Rao M. Raghavendra ◽  
Kodaganur Srinivasachar Gopinath ◽  
Ramesh Bilimagga S ◽  
Ravi B Diwakar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Supportive Therapy ◽  
Nausea And Vomiting ◽  
Breast Cancer Patients ◽  
Anticipatory Nausea ◽  
Yoga Intervention ◽  
Antiemetic Regimen ◽  
Primary Predictor

1093 Background: Chemotherapy induced nausea and vomiting (CINV) is affected by both pretreatment patient factors, chemotherapy and antiemetic regimen and psychological interventions. In this study we evaluated the effects of mind body intervention such as yoga in modulating CINV outcomes controlled for the above factors. Methods: Chemotherapy naïve breast cancer patients with stage II and III disease participating in a randomized controlled trial comparing yoga (n=45) vs. supportive therapy (n=53) were assessed for CINV outcomes during adjuvant chemotherapy. Morrows Assessment of nausea and emesis was used to asses CINV symptoms including their frequency, severity and anticipatory nature. We developed a multiple regression analyses to test the role of intervention on CINV beyond that explained by the independent prognostic factors [age (<50/≥50 years), stage of disease (II vs III), menopausal status (pre vs post), antiemetic regimen (5HT3 antagonists vs. antidopaminergics), administration of anxiolytics (yes/ no) and type of chemotherapy regimen (FAC vs. CMF)] that were included in model A. Model B includes these six variables plus intervention (yoga vs. supportive therapy) in predicting nausea and vomiting outcomes. Results: Intervention emerged as a primary predictor for nausea frequency (β= -0.38, p=0.002), intensity (β= -0.44, p=0.001 ), anticipatory nausea frequency (β=-0.26 , p= 0.04) and intensity (β=-0.38 , p=0.004 ). Age group emerged as a primary predictor for anticipatory vomiting frequency (β=-0.39 , p=0.01 ) and secondary predictor for nausea frequency (β=-0.41, p= 0.006). Administration of anxiolytics emerged as a primary predictor for vomiting intensity (β=-0.40, p= 0.001) and secondary predictor for anticipatory nausea frequency (β=-0.26 , p= 0.05). Conclusions: Yoga intervention influences CINV outcomes when controlled for pretreatment and pharmacological factors during chemotherapy in breast cancer patients poorly controlled for nausea and vomiting.

Sign in / Sign up

Export Citation Format

Share Document